Navigation Links
Drug Combo Helps Fight Marfan Syndrome
Date:10/2/2007

Inherited condition can lead to sudden cardiac death

TUESDAY, Oct. 2 (HealthDay News) -- Treatment with the heart drug perindopril, along with a beta blocker, may help reduce certain cardiac complications of the hereditary disorder Marfan syndrome, research shows.

Marfan syndrome, which principally affects connective tissues, is often characterized by excessive bone elongation and joint flexibility, and eye and cardiovascular system abnormalities. Progressive dilation and rupture of a major blood vessel, the aorta, are the most serious complications and the most common cause of premature death in people with the disorder, according to background information in the study.

Beta blockers are the current standard treatment for Marfan syndrome, but may not be as effective in treating aortic wall degeneration as other therapies. Previous research has found that ACE inhibitors such as perindopril help reduce arterial stiffness.

Reporting in the Oct. 3 issue of the Journal of the American Medical Association, Australian researchers at the Baker Heart Research Institute examined the effectiveness of perindopril in adult Marfan syndrome patients receiving standard beta-blocker therapy. Ten patients received 8 milligrams/day of perindopril while seven others received a placebo for 24 weeks.

"The major novel finding of our study was that perindopril therapy for 24 weeks reduced aortic diameters relative to placebo in both systole (the contraction of the chambers of the heart) and diastole (the expanding of the chambers of the heart) in patients with Marfan syndrome taking standard beta-blocker therapy," the study authors wrote.

"In systole, perindopril reduced the progression of aortic dilatation observed in the placebo group. However, in diastole, perindoperil actually reduced aortic diameters below baseline levels," they noted.

The researchers recommended a larger, longer-term clinical trial.


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Drug Combo Works Better for children with ADHD, Tics
2. Scanning Combo Helps Detect Lung Cancer
3. Relief From Asthma With New Combo Therapy
4. Calcium-Vitamin D Combo For Reduced Fracture Risk
5. Drug Combo Improves Performance Of Multiple Sclerosis Drug
6. Alcohol-illusion: Alcohol and Energy Drinks Combo, Maintains Sobriety?
7. HER-2 Positive Breast Cancer Patients May Benefit With a Combo Drug Strategy
8. The Combo Treatment Is Effective to Treat Type 1 Diabetes in Mice
9. Doomed Duo: Obesity and Type 2 Diabetes Combo, Can Nip Life in the Bud
10. Arimidex-Herceptin Combo Therapy For Breast Cancer-Clinical Trial Findings
11. Fuzeon and MK-0518 Combo Holds Promise For HIV
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Pharmacy Technician Employment Increasing Up to 32% By 2016 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 3Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 4ARKRAY, Inc. Announces Partnership With scil animal care company for the SPOTCHEM(TM) EZ Analyzer 2Escalon 28R 29 Subsidiary Sonomed Introduces New PacScan 28TM 29 Plus A Scan and Pachymeter 5667 1Escalon 28R 29 Subsidiary Sonomed Introduces New PacScan 28TM 29 Plus A Scan and Pachymeter 5667 2Escalon 28R 29 Subsidiary Sonomed Introduces New PacScan 28TM 29 Plus A Scan and Pachymeter 5667 3Escalon 28R 29 Subsidiary Sonomed Introduces New PacScan 28TM 29 Plus A Scan and Pachymeter 5667 4Escalon 28R 29 Subsidiary Sonomed Introduces New PacScan 28TM 29 Plus A Scan and Pachymeter 5667 5Escalon 28R 29 Subsidiary Sonomed Introduces New PacScan 28TM 29 Plus A Scan and Pachymeter 5667 6Biomoda Enters Final Stage of Patient Testing for Phase II Lung Cancer Clinical Study 5663 1Biomoda Enters Final Stage of Patient Testing for Phase II Lung Cancer Clinical Study 5663 2NASCAR Camping World Truck Series Driver Aric Almirola Waves the Yellow Flag at Warning Signs of Skin Cancer 5659 1NASCAR Camping World Truck Series Driver Aric Almirola Waves the Yellow Flag at Warning Signs of Skin Cancer 5659 2NASCAR Camping World Truck Series Driver Aric Almirola Waves the Yellow Flag at Warning Signs of Skin Cancer 5659 3
Other Medicine Technology:CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 2CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 3CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 4CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8